SOTIO Showcases New Data on SOT201 Immunocytokine, VICTORIA-01 Clinical Study, and BOXR CAR-T Advancements at 2024 SITC Annual Meeting
- Global VICTORIA-01 Phase 1 study evaluating safety and efficacy of SOT201 in advanced solid tumor patients currently enrolling;
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced data supporting SOT201, its next-generation PD-1-targeting immunocytokine. The company also reported advancements in its BOXR cell therapy platform, introducing an innovative chimeric PGC-1α transgene to boost CAR T cell efficacy in patients with solid tumors. SOTIO will be presenting three posters highlighting these advancements at the 2024 Society for Immunotherapy of Cancer Meeting, taking place November 6–10 in Houston, TX, U.S.
SOTIO Announces Upcoming Poster Presentations at the 2024 SITC Annual Meeting
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at the 2024 Society for Immunotherapy of Cancer Meeting taking place November 6 - 10, 2024, in Houston, TX.
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
- Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platform;
- Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs;
- Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million;
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
